12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Colobreathe colistimethate sodium regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Colobreathe colistimethate sodium from Forest to treat chronic pulmonary infection caused by Pseudomonas aeruginosa in cystic fibrosis (CF) patients if nebulized colistimethate, a generic antibiotic, is not tolerated. The decision is contingent...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >